LS9

LS9 Announces Second Partnership with Procter & Gamble

LS9 Announces Second Partnership with Procter & Gamble

February 7, 2011

SOUTH SAN FRANCISCO, CA - February 7, 2011 - LS9, Inc. today announced the initiation of a second development and commercialization partnership with Procter & Gamble (NYSE: PG). This additional partnership draws on LS9's unique technology to broaden the portfolio of renewable chemicals to be used in P&G's consumer products.

Accuri Cytometers, Inc.

BD Announces Agreement to Acquire Accuri Cytometers, Inc.

BD Announces Agreement to Acquire Accuri Cytometers, Inc.

February 7, 2011

 

BG Medicine, Inc.

BG Medicine Announces Pricing of Initial Public Offering

BG Medicine Announces Pricing of Initial Public Offering

February 4, 2011

WALTHAM, Mass.--(BUSINESS WIRE)--BG Medicine (NASDAQ: BGMD) today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a price of $7.00 per share, before underwriting discounts and commissions. All shares are being sold by the Company.

AVEO Pharmaceuticals, Inc.

AVEO Pharmaceuticals Initiates Enrollment in a Phase 2 Exploratory Biomarker Study of Tivozanib

AVEO Pharmaceuticals Initiates Enrollment in a Phase 2 Exploratory Biomarker Study of Tivozanib

February 1, 2011

CAMBRIDGE, Mass., Feb 01, 2011 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that it has initiated patient enrollment in a multi-center Phase 2 exploratory biomarker study of tivozanib, its lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, in patients with renal cell carcinoma (RCC).

Joule Unlimited, Inc.

Joule Biotechnologies Names Bill Sims President and CEO

Joule Biotechnologies Names Bill Sims President and CEO

July 27, 2009

Cambridge, Mass.—July 27, 2009—Joule Biotechnologies, Inc., an innovative bioengineering startup developing game-changing alternative energy solutions, today announced the appointment of Bill Sims as president and CEO. Sims brings nearly 30 years of experience growing both emerging and established companies across multiple technology and product sectors. In addition to his new position, he will continue to serve on the company’s board of directors.

Mascoma Corporation

Mascoma Announces Feedstock Processing and Lignin Supply Agreement with Chevron Technology Ventures

Mascoma Announces Feedstock Processing and Lignin Supply Agreement with Chevron Technology Ventures

September 14, 2009

 Lebanon, New Hampshire – September 14, 2009 – Mascoma Corporation today announced that it has entered into a feedstock processing and lignin supply agreement with Chevron Technology Ventures (CTV), a division of Chevron U.S.A., Inc.

Under terms of the agreement, CTV will provide various sources of lignocellulosic feedstock to Mascoma. Mascoma will then convert the feedstock to cellulosic ethanol through its proprietary process, which produces lignin as a by-product. Mascoma will provide this lignin to CTV for evaluation.

VisEn Medical, Inc.

VisEn Launches New Cat B 680 FAST™ Fluorescence Molecular Imaging Agent

VisEn Launches New Cat B 680 FAST™ Fluorescence Molecular Imaging Agent

January 19, 2010

Extends VisEn’s Leading Fluorescence Molecular Imaging Agent Portfolio to Enable Expanded Readouts of Key Protease Biomarkers in Research and Drug Development

BEDFORD, MA (January 19, 2010)—VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the commercial launch of its new Cat B 680 FAST™ imaging agent for measuring and monitoring cathepsin B activity associated with disease progression and therapeutic response in vivo.

Receptos, Inc.

Receptos Initiates Clinical Trials for S1P1 Agonist Program, Aimed at Multiple Sclerosis

Receptos Initiates Clinical Trials for S1P1 Agonist Program, Aimed at Multiple Sclerosis

January 27, 2011

First subject dosed in Phase 1 Single Ascending and Multiple Ascending Dose Safety Study

Concert Pharmaceuticals, Inc.

Concert Pharmaceuticals Enters Into a Cooperative Research and Development Agreement with Walter Reed Army Institute of Research to Evaluate Neuroprotective Drug Compound

Concert Pharmaceuticals Enters Into a Cooperative Research and Development Agreement with Walter Reed Army Institute of Research to Evaluate Neuroprotective Drug Compound

February 2, 2011

Advances Concert’s R&D for Novel Drugs to Treat Seizure-Generating Diseases and Injuries

Pervasis Therapeutics, Inc.

Pervasis Therapeutics to Develop Novel Cell-Based Approach to Target Tumor Environment, Prevent Cancer Recurrence

Pervasis Therapeutics to Develop Novel Cell-Based Approach to Target Tumor Environment, Prevent Cancer Recurrence

January 19, 2011

Bolstered by Landmark Research and Multiple Preclinical Studies, Groundbreaking Therapy Holds Promise to Deliver Safe, Effective Cell Therapy Treatment for Solid Tumors